Jotam G Pasipanodya

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi Pulmonary impairment after tuberculosis and its contribution to TB burden
    Jotam G Pasipanodya
    Department of Medicine, University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, USA
    BMC Public Health 10:259. 2010
  2. ncbi Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis
    Mauricio Vecino
    Department of Medicine, University of North Texas Health Science Center at Fort Worth, TX, United States
    J Infect Public Health 4:244-52. 2011
  3. ncbi Non-hispanic whites have higher risk for pulmonary impairment from pulmonary tuberculosis
    Jotam G Pasipanodya
    Department of Internal Medicine, UNT Health Science Center at Fort Worth, Fort Worth, TX, USA
    BMC Public Health 12:119. 2012
  4. ncbi Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis
    Jotam G Pasipanodya
    Department of Medicine, Texas College of Osteopathic Medicine, University of North Texas Health Science Center at Fort Worth, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
    Chest 132:1591-8. 2007
  5. ncbi Pulmonary impairment after tuberculosis
    Jotam G Pasipanodya
    Department of Medicine, University of North Texas Health Science Center at Fort Worth, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
    Chest 131:1817-24. 2007
  6. ncbi Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability
    Shashikant Srivastava
    Department of Medicine, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Infect Dis 204:1951-9. 2011
  7. ncbi Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection
    Mamta K Jain
    UT Southwestern Medical Center, Department of Internal Medicine, Dallas, TX, USA
    Antimicrob Agents Chemother 57:1115-20. 2013
  8. ncbi A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs
    Jotam G Pasipanodya
    Department of Medicine, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Curr Opin Pharmacol 11:457-63. 2011

Collaborators

Detail Information

Publications8

  1. ncbi Pulmonary impairment after tuberculosis and its contribution to TB burden
    Jotam G Pasipanodya
    Department of Medicine, University of North Texas Health Science Center at Fort Worth, Fort Worth, Texas, USA
    BMC Public Health 10:259. 2010
    ..We assessed the burden of TB including pulmonary impairment after tuberculosis in Tarrant County, Texas using Disability-adjusted Life Years (DALYs)...
  2. ncbi Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis
    Mauricio Vecino
    Department of Medicine, University of North Texas Health Science Center at Fort Worth, TX, United States
    J Infect Public Health 4:244-52. 2011
    ..The stability of PIAT and the relationship of PIAT to the duration of delay in tuberculosis diagnosis and treatment have not been fully characterized...
  3. ncbi Non-hispanic whites have higher risk for pulmonary impairment from pulmonary tuberculosis
    Jotam G Pasipanodya
    Department of Internal Medicine, UNT Health Science Center at Fort Worth, Fort Worth, TX, USA
    BMC Public Health 12:119. 2012
    ..Pulmonary impairment after tuberculosis (PIAT) contributes heavily to the societal burden of TB. Individual impacts associated with PIAT may vary by race/ethnicity or socioeconomic status...
  4. ncbi Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis
    Jotam G Pasipanodya
    Department of Medicine, Texas College of Osteopathic Medicine, University of North Texas Health Science Center at Fort Worth, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
    Chest 132:1591-8. 2007
    ..We measured HRQoL pattern changes and the usefulness of the SGRQ in their ascertainment...
  5. ncbi Pulmonary impairment after tuberculosis
    Jotam G Pasipanodya
    Department of Medicine, University of North Texas Health Science Center at Fort Worth, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
    Chest 131:1817-24. 2007
    ..Pulmonary impairment subsequent to a cure of pulmonary tuberculosis has been described only in selected populations...
  6. ncbi Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability
    Shashikant Srivastava
    Department of Medicine, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Infect Dis 204:1951-9. 2011
    ..Performance of a randomized controlled trial in which some patients are randomized to nonadherence would be unethical; therefore, other study designs should be utilized...
  7. ncbi Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection
    Mamta K Jain
    UT Southwestern Medical Center, Department of Internal Medicine, Dallas, TX, USA
    Antimicrob Agents Chemother 57:1115-20. 2013
    ..Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy...
  8. ncbi A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs
    Jotam G Pasipanodya
    Department of Medicine, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Curr Opin Pharmacol 11:457-63. 2011
    ....